For COVID-19 and vaccination updates, view our information for the community. If you're experiencing symptoms, call your primary care provider.

Decorative dot pattern background image.
Decorative blue shape background image. Decorative blue shape background image. Decorative blue shape background image. Decorative blue shape background image.

Alliance A041701

Trial Overview

Official Title

A Randomized Phase II/III Study of Conventional Chemotherapy +/- Uproleselan (GMI-1271) in Older Adults with Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy

Study Purpose

To compare the usual treatment alone to using uproleselan plus the usual treatment.

Diagnosis

Acute Myeloid Leukemia

Eligibility

No prior chemotherapy for MDS or AML

Patients must sign an approved informed consent and authorization permitting release of personal health information.

Intervention

  • Group 1: Daunorubicin + Cytarabine (usual approach group)
  • Group 2: Daunorubicin + Cytarabine + Uproleselan (study drug)

Patients will either get the usual treatment or the usual treatment plus the study drug for up to 5 months. After treatment is finished the doctor will continue to follow up and watch for side effects for up to 5 years.

Key Participation Requirements
Gender
Male or Female
Age
60 years and older
Enrollment Status
Suspended
Phase
Phase II
Methodist Health System Trial Code
A041701